Sep 27, 2018

Cure Alzheimer's Fund - Progress with the Research of Alzheimer’s Disease

You won't want to miss this year's Cure Alzheimer's Fund Symposium. The participants will be discussing the latest and most important developments in Alzheimer's research (very exciting). They will also update the newest National Institute of Health guidelines and funding for Alzheimer's research.


The Cure Alzheimer's Fund's (CAF) annual research symposium is now available to watch.

The Cure Alzheimer's Fund's (CAF) annual research symposium is now available to watch.

Watch Now


This year's topic -

Progress with the Research of Alzheimer’s Disease


The Cure Alzheimer's Fund is a non-profit organization dedicated to funding research with the highest probability of preventing, slowing or reversing Alzheimer’s disease.
  • They are the only research organization I recommend for donations. I know them well. And, they have received the Alzheimer's Reading Room Gold Seal of Approval.

Read these words closely - funding research with the highest probability of preventing, slowing or reversing Alzheimer’s disease.

Did you know?

100 Percent of every dollar you donate to the CAF goes directly into Alzheimer's Research.

Since its founding, CureAlz has contributed more than $74,000,000 to research, and its funded initiatives have been responsible for several key breakthroughs …

  • including a potential treatment recently selected by the National Institutes of Health (NIH) for its elite “Blueprint” drug discovery program, 
  • and the ground-breaking “Alzheimer’s in a Dish” study, which promises to greatly accelerate drug testing and was reported by The New York Times as a “giant step forward”.

CureAlz supports some of the best scientific minds in the field of Alzheimer’s research and does so without any financial gain for its founders or donors.

Fully 100% of funds raised by Cure Alzheimer’s Fund go directly to research.
The Board of Directors covers all overhead expenses.

Note: The Board and Founders of the Cure Alzheimer's Fund have donated an additional $31,508,821 out of their own pockets to cover the cost of running the fund and for the benefit of Alzheimer's research.

The Cure Alzheimer's Fund is ranked #1 in Alzheimer's by Charity Navigator.


For many years, Alzheimer’s disease research was completely stifled by a lack of funding. Pharmaceutical companies were too wary of past failures to fund any new drug development.

The drug pipeline was coming up dry, and researchers weren’t encouraged to think big or bold. The Cure Alzheimer's Fund has stepped into the gap and changed the face of Alzheimer's Research.

Subscribe to the Alzheimer's Reading Room
Email:

The Cure Alzheimer's Fund is a 501(c)(3) nonprofit organization founded in 2004 by three families frustrated by the slow pace of research.

Leveraging their experience in venture capital and corporate start-ups, our founders (Jeff Morby, Jacqui Morby, Henry McCance, and Phyllis Rappaport) came together to build a new Alzheimer’s research fund designed to dramatically accelerate research, make bold bets, and focus exclusively on finding a cure.

Their Research Leadership Group is an all-star team of scientists working at premier research institutions across the country, regularly conferring with one another on the progress and impediments in their research and constantly sharing their data.

Their goal is to stop Alzheimer’s disease through early prediction, prevention, and effective intervention leading to a cure.

Progress with the Research of Alzheimer’s Disease


The Panelist

Jon Hamilton (Moderator)

NPR Correspondent, Science Desk

Jon Hamilton is a correspondent for NPR’s Science Desk. Currently he focuses on neuroscience, health risks, and extreme weather. In 2009, he received the Michael E. DeBakey Journalism Award for his piece on the neuroscience behind treating autism. Before joining NPR in 1998, Hamilton was a media fellow with the Henry J. Kaiser Family Foundation studying health policy issues.

Teresa Gomez-Isla, M.D.

Massachusetts General Hospital

Teresa Gomez-Isla, M.D., is a neurologist with Massachusetts General Hospital and an Associate Professor at Harvard Medical School, specializing in the investigation of the neurobiology of normal aging, Alzheimer’s disease, and other dementia. Her lab focuses on the development and characterization of transgenic mouse models of Alzheimer’s disease and on testing novel therapeutic strategies. Research is also conducted with human brain tissue from individuals who suffered from Alzheimer’s disease while alive.

Ronald C. Petersen, M.D., Ph.D.

Mayo Clinic

Ronald C. Petersen, M.D., Ph.D., focuses on investigations of cognition in normal aging, mild cognitive impairment, and dementia. He directs the Mayo Clinic Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging, both of which involve the study and characterization of aging individuals over time with an emphasis on neuroimaging and biomarkers. He is a recipient of the 2004 MetLife Award for Medical Research in Alzheimer’s Disease, the 2005 Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Disorders of the American Academy of Neurology. Dr. Peterson is a member of the Cure Alzheimer’s Fund Research Leadership Group.

Robert Vassar, Ph.D.

Northwestern University

Robert Vassar, Ph.D., is a Professor of Cell and Molecular Biology at Northwestern University. His ongoing research focuses on the role of Abeta and BACE1 in normal biological processes and in disease mechanisms of relevance to Alzheimer’s disease. His lab is interested in the role of inflammation in Alzheimer’s disease pathophysiology, novel transgenic and knockout mouse models of Alzheimer’s disease, and molecular changes that may occur during brain aging leading to neurodegeneration. Dr. Vassar is a member of the Cure Alzheimer’s Fund Research Leadership Group.


Related

The Last 25 Articles in the Alzheimer's Reading Room

About the Alzheimer's Reading Room

Need Help? Search Our Award Winning Knowledge Base for Answers to Your Questions About Alzheimer's and Dementia